Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 May 2018

Indication(s)

- Prometax hard capsules
- Prometax oral solution

Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.



- Prometax transdermal patch
Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000255
Orphan designation No
Date First Approved 04-12-1998
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novartis Europharm Ltd.